$DOCS

Sitaram Siddharth sold $38K of DOCS

Sitaram Siddharth (Chief Accounting Officer) sold 1,732 shares of Doximity, Inc. (DOCS) at $22.02 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Jul 20, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

This provides a concrete datapoint on insider ownership reduction by the CFO, but it does not introduce new fundamentals or guidance.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 framing reduces interpretive weight.

03

What to watch

The article does not state whether the sale was part of a larger series, nor does it provide option exercises or purchases that could offset net insider selling.

Relevance 2/10Novelty 4/10Timing: Filed 2026-07-20, disclosing the 2026-07-15 insider sale details.

Background

The article is an SEC Form 4 insider transaction disclosure for Doximity, Inc. (DOCS).

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

SEC Form 4 shows Doximity CFO Sitaram Siddharth sold 1,732 shares at $22.0200 on a 10b5-1 plan, totaling $38,138.64.

Expected impact

Likely minimal near-term impact; treat as low-signal unless paired with other disclosures.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale, and the article provides no new operational, financial, or regulatory catalyst beyond the transaction details.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; monitor for additional insider sales or changes in trading patterns.

Key entities

  • Doximity, Inc.

    Company whose insider transaction is disclosed via SEC Form 4.

  • Sitaram Siddharth

    Chief Accounting Officer who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.